POSITIVELY PRECISE.

We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More

Pipeline

Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more

HEARTS & MINDS BLOG

A Closer Look – June 2018

As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive… more

Posted by mlowe@esperion.com

Key Insights from March 2018 ACC: CLEAR Outcomes Looking Even CLEARer After ODYSSEY – Updated ICER Cost-Effectiveness Analysis A Win for Patients and for the Bempedoic Acid Franchise

Our Lipid Management Team attended the 67th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando this… more

Posted by mlowe@esperion.com

Help with Understanding Liver Function Test Increases: From the Lipid Management Team

We recently announced positive results from our first pivotal phase 3 study (Study 4 or the 048 study) of bempedoic… more

Posted by mlowe@esperion.com